Horizon Pharma is set to acquire Dublin-based Vidara Therapeutics in a merger worth about $660 million, the companies announced on March 19.
Massachusetts-based Idenix Pharmaceuticals has filed patent infringement cases against Gilead Sciences and its European subsidiaries in France, Germany and the UK.
A contraction of 0.3 percent in Ireland’s economy last year has been linked to the expiry of several key pharmaceutical patents.
The Unified Patent Court has clarified its opt-out scheme, making clear that when a European patent has been opted out of the scheme, its associated supplementary protection certificate will follow.
While the political will exists for the introduction of the Unified Patent Court next year, much more still needs to be done, according to Adam Cooke, a partner in DLA Piper's IP and technology group.
A key concern for lawyers and in-house counsels practising in the pharmaceutical industry is the disclosure of clinical data, according to the co-chairs of DLA Piper's Global Life Sciences sector, Bonella Ramsay and John Dougherty.
Bayer has announced that it plans to acquire Dihon Pharmaceutical Group, a Chinese company that makes over-the-counter (OTC) and herbal traditional Chinese medicine (TCM) products.
Bayer will acquire Norwegian pharmaceutical company Algeta for €2.1 billion ($2.9 million), it announced on Monday.
Actavis has announced another expansion with the $25 billion acquisition of US pharmaceutical company Forest Laboratories.
Baker & McKenzie LLP has added to its IP team with the appointment of Hiroshi Sheraton as partner in its London office.